Table 1

Virological response in HDV patients treated with pegIFNα, BLV with or without pegIFNα, pegIFNλ, and LNF+RTV with or without pegIFNα

Treatment strategiesNo of patientsHDV RNA levels (log IU/ml)Duration of therapy
(weeks)
Virological response
HDV RNA <LLoQHDV RNA: >2 log IU/mL decline or <LLoQHDV RNA decline
(mean or median log IU/mL)
BaselineDuring therapyOff-therapyDuring therapyOff-therapyDuring therapyOff-therapy
Week 24Week 48Week 24Week 24Week 48Week 24Week 24Week 48Week 24
PegIFNα 180 μg QW*155.444813.3%0%0%−1.29−0.26
BLV 2 mg every day mono*156.394813%13.3%6.7%33.3%−2.84−1.08
BLV 10 mg every day mono*155.64827%40%33.3%46.7%−4.58
BLV 2 mg every day +pegIFNα 180 μg QW*155.484867%80%53.3%73.3%−5.21−4.04
BLV 10 mg every day +pegIFNα 180 μg QW*155.94860%86.7%6.7%33.3%−6.09
LNF 50 mg two times per day+RTV 100 mg two times per day†122442%39%−1.66
LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNα 180 μg QW†42450%89%−3.71
PegIFNλ 180 μg QW‡143.864836%36%−2.72−2.3−1.86
LNF 50 mg two times per day+RTV 100 mg two times per day+pegIFNλ 180 μg QW§264.742427%19%96%−3.4
  • *MYR203 study, HDV RNA assay LLoQ 10 IU/mL.

  • †LOWR-2 study, Robogene assay, LLoQ 14 IU/mL.

  • ‡LIMT study, Robogene assay, LLoQ 14 IU/mL.

  • §LIFT HDV study, Quest Diagnostics Assay, HDV RNA LLoQ <40 IU/mL or <1.6 log IU/ml; ‘-’: data not published or not presented.

  • BLV, bulevirtide; HDV, hepatitis D virus; LNF, lonafarnib; pegIFNα, pegylated interferon-α; RTV, ritonavir.